Trial Profile
Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 12 Nov 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 25 Jul 2014 New trial record